ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE RISK FACTORS AND OCCURRENCE OF VENOUS THROMBOEMBOLISM: A TIME-DEPENDENT ANALYSIS by Wattanakit, Keattiyoat et al.
Association between cardiovascular disease risk factors and
occurrence of venous thromboembolism:
A time-dependent analysis
Keattiyoat Wattanakit1, Pamela L. Lutsey2, Elizabeth J. Bell2, Heather Gornik3, Mary
Cushman4, Susan R. Heckbert5, Wayne D. Rosamond6, and Aaron R. Folsom2
1Cardiology, HeartCare Midwest, Peoria, Illinois, USA
2Epidemiology & Community Health, School of Public Health, University of Minnesota,
Minneapolis, Minnesota, USA
3Vascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
4Department of Medicine, University of Vermont, Colchester, Vermont, USA
5Epidemiology, University of Washington, Seattle, Washington, USA
6Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
Summary
Apart from obesity, it remains controversial whether atherosclerosis and its cardiovascular risk
disease (CVD) factors are associated with risk of venous thromboembolism (VTE). Using data
from the Atherosclerosis Risk in Communities study (ARIC), we evaluated associations between
CVD risk factors and incident VTE in a cohort of 15,340 participants who were free a history of
VTE and/or anticoagulant use on enrolment. The CVD risk factors were updated during the
follow-up period. Over a mean follow-up time of 15.5 years (237,375 person-years), 468
participants had VTE events. Adjusting for demographic variables and body mass index (BMI),
current smokers were at greater risk [HR of 1.44 (95% CI: 1.12–1.86)] compared to non-smokers.
There was a positive monotonic association between BMI and VTE risk. Individuals with a BMI
≥35 kg/m2 had a HR for VTE of 3.09 (95%CI: 2.26–4.23) compared to those with normal BMI
(<25 kg/m2). Greater physical activity was associated with lower VTE risk in a demographic
adjusted model; however, this association became non-significant following adjustment for BMI.
Alcohol intake, diabetes, hypertension, high-density lipoprotein and low-density lipoprotein
cholesterol, and triglycerides were not associated with VTE risk. In conclusion, among the well-
established CVD risk factors, only current smoking and obesity were independently associated
with VTE risk in this large cohort where risk factors were updated serially during follow-up. This
finding corroborates that the pathogenesis of venous disease differs from that of atherosclerotic
disease.
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Despite substantial interest, it remains unclear whether atherosclerotic cardiovascular
disease (CVD) is related to risk of deep-vein thromboembolism (DVT) and pulmonary
embolism (PE), collectively referred to as venous thromboembolism (VTE). In general,
case-control studies have found a positive association between markers of subclinical
atherosclerotic CVD and risk of VTE (1,2), while prospective cohort studies reported no
association (3, 4). It is generally believed that if an association between atherosclerotic CVD
and VTE exists, the mechanism is presumed to relate to the sharing of common risk factors
between the two diseases. To date, among CVD risk factors, only obesity is consistently
associated with VTE risk (5–7), whereas the roles of diabetes, hypertension, smoking, total
cholesterol, high density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol,
triglycerides, alcohol non-use, and physical inactivity are less clear (7–9). One possible
reason for the lack of clarity is that these CVD risk factors, which are known to fluctuate
over time, were typically measured only once at baseline in existing cohort studies (years
before VTE events), or once after VTE cases were identified in case-control studies. It may
be difficult to demonstrate associations with risk factors when, in cohort studies, VTE events
occur years after the initial baseline measurements. To date, there is only one study that has
analysed the association between CVD risk factors and VTE events in a time-dependent
manner (6). Using data from the ARIC, we therefore conducted a study to investigate the
association between CVD risk factors and VTE risk, updating risk factors during follow-up.
The findings of this study should help clarify whether the contribution of risk factors to
venous disease differs from that of atherosclerotic disease.
Materials and methods
Study population
The ARIC Study is a community-based, prospective study that investigates the etiology and
natural history of CVD. Detailed descriptions of the study design and objectives have been
published elsewhere (10). Briefly, the study enrolled 15,792 adults aged 45 to 64 years at
baseline from four US communities: Forsyth County, NC; Jackson, MS; Minneapolis, MN;
and Washington County, MD. Cardiovascular risk factors were collected at the baseline
examination conducted between 1987 – 1989. The cohort underwent reexamination visits at
roughly three-year intervals, with a 93% return rate for visit 2 (1990–1992), 86% for visit 3
(1993–1995), and 81% for visit 4 (1996–1998). Informed consent was obtained from
participants, with approval of methods by the institutional review boards at each study
center.
Measurement of cardiovascular risk factors
At the baseline visit, the participants underwent a standardised medical history and
examination that included interviews and fasting venipuncture. Participants were classified
as never, former, or current alcohol drinkers. Pack-years of smoking were calculated by
multiplying the average number of cigarettes per day by the number of years smoked and
dividing by 20. Physical activity was assessed using the Baecke sports questionnaire, with
scores ranging from 1 (low) to 5 (high), and participants were categorised as low (<2)
moderate (2 to 4), or high (≥4) (11). Participants were asked to bring all current medications.
Medication types were recorded, including cholesterol-lowering medications, beta-blockers,
angiotensin-converting enzyme inhibitors, or other antihypertensive medications.
Anthropometrics, including weight and height, were obtained while the participant was
wearing a scrub suit. Body mass index (BMI) was calculated as weight in kilograms divided
by the square of height in meters (kg/m2).
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Fasting blood samples were drawn from an antecubital vein for measurement of lipids,
glucose, and chemistries. Laboratory assays for triglycerides, high-density lipoprotein
(HDL) cholesterol, and calculated LDL cholesterol were performed in standardised research
laboratories (12). Diabetes was defined as a fasting serum glucose level ≥7.0 mM (126 mg/
dl), non-fasting glucose level ≥11.1 mM (200 mg/dl), physician diagnosis of diabetes, or
current use of any diabetes medication. Hypertension was defined as seated diastolic blood
pressure (DBP) ≥90 mmHg, systolic blood pressure (SBP) ≥140 mmHg, or use of
antihypertensive medications within the past two weeks.
VTE identification and classification
ARIC participants were followed through 2005 and were contacted annually by telephone or
through clinic visits. Hospitalisations were identified by participants and by surveillance of
local hospital discharge lists within ARIC sites. All records with possible VTE were
identified and copied.
DVT was defined on the basis of duplex ultrasound or venogram or, in rare cases, by
impedance plethysmography, computed tomography (CT), or autopsy (13). Definite PE
required ventilation/perfusion scanning showing multiple segmental or subsegmental
mismatched perfusion defects, or a positive pulmonary angiogram, CT, or autopsy. VTE
events were further classified as unprovoked or provoked (occurring within 90 days of major
trauma, surgery, hospitalisation, or marked immobility or associated with active cancer or
chemotherapy).
Statistical analyses
Of 15,792 ARIC participants at baseline, we excluded, due to small numbers, 48 participants
who were neither white nor African-American participants and 55 African-Americans from
Washington County and Minneapolis suburbs. We further excluded 89 participants with
anticoagulant use at baseline, and 260 participants who had a baseline history of VTE. The
123 participants who reported anticoagulant use (confirmed by checking medication bottles)
during follow-up visits were censored at the visit prior to this use. Follow-up time was
calculated as the time elapsed between the baseline visit and the first VTE event, death, date
of last known contact, or December 31,2005. Less than 7% of the cohort was lost to follow-
up for VTE hospitalisations.
Means and counts of participant characteristics by visit were computed. Cox regression was
used to calculate hazard ratios (HR) and 95% confidence intervals (CI) of incident VTE by
CVD risk factor level. Because these risk factors change over time, and more recent levels
may be more highly associated with VTE risk, we modeled the risk factor variables as time-
dependent exposure variables using data from each of the four ARIC visits between 1987–
1998. An analysis involving time-dependent variables uses not just the baseline values for
the risk factors under consideration, but also incorporates the values at later examination
visits (in this case, ARIC visits 2–4). The HRs that are estimated are essentially for the
averaged value of the risk factors, rather than a single baseline value. The advantage of this
analysis is that it more accurately represents the long-term level of the risk factor by
accommodating changes in risk factors over time. If a participant was missing a risk factor
value for a given visit, the previous visit’s risk factor value was carried forward until another
value was obtained.
HRs were computed with each risk factor level category modelled as an indicator variable so
that there was no assumption of linearity. Linear trends across the categories were calculated
by including the risk factor categories in the model as a continuous variable. A test for
interaction for each risk factor with log(time) showed that the proportional hazards
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assumption was not violated. Model 1 adjusted for age (continuous), race (white, African
American), field center (Forsyth County, Jackson, Minneapolis, Washington County), and
sex (male, female). Model 2 additionally adjusted for BMI (continuous) as a time-varying
covariate. Multiplicative interactions of each CVD risk factor and age (< 55 years, >55 years
at baseline) were also tested using cross-product terms.
Blood pressure and lipids could change over time due to use of anti-hypertensive and lipid
lowering medications. Therefore, we accounted for medication use by including as time-
varying covariates the measured baseline SBP, DBP, and lipid values together with use of
anti-hypertensive (yes, no) and lipid lowering (yes, no) medications. As a secondary
analysis, for those on anti-hypertensive medications a constant of 15 was added to the
measured blood pressure values (14). For those on lipid lowering medications, constants
(depending on specific type of medications) were added to the original LDL and HDL
cholesterol and triglycerides (15).
Results
Among 15,340 participants at the first visit, the mean age was 54 years. Almost 27% were
African-Americans, and 45% were men. 468 participants had VTE events over the mean
follow-up time of 15.5 years (237,375 person-years). Table 1 shows risk factor levels at each
visit. Compared to baseline, the percentage of participants who reported being active (in
quartile 4) increased (19.9% at visit 1 vs. 23.3% at visit 3). The percentage of participants
who used tobacco or alcohol decreased (26.2% at visit 1 vs. 15.0% at visit 4 for current
tobacco use and 14.2% at visit 1 vs. 11.3% at visit 4 for alcohol use ≥100 g/weeks). The
prevalence of obesity and diabetes increased over the years. At visit 1,9% of participants had
BMI ≥35 kg/m2 and 12% had diabetes. At visit 4, the prevalence had increased to 12.2%and
16.7%, respectively. The prevalence of hypertension also increased from 34.9% at visit 1 to
47.1% at visit 4. On the other hand, LDL cholesterol declined (26.0% with LDL ≥160 at
visit 1 vs. 12.6% with LDL ≥160 at visit 4) over the years, as treatment increased.
Table 2 shows HRs for incident VTE (provoked and unprovoked) by risk factor levels. In
the demographic adjusted model, a higher level of physical activity was associated with a
lower risk of incident VTE. This association lost statistical significance after adjustment for
BMI. After adjustment for demographic variables and BMI, current smoking was associated
with a 44% greater risk of VTE than non-smoking. There was a linear association between
BMI and VTE risk (ptrend = <0.0001). Participants with a BMI ≥35 kg/m2 were at three-fold
increased risk of VTE compared to those with a normal BMI (<25 kg/m2). This association
remained statistically significant when separately analysed for unprovoked and provoked
VTE. Alcohol intake was unrelated to risk of VTE events.
Of the physiologic characteristics, in the demographic-adjusted model diabetes was
associated with greater risk of incident VTE, while high HDL cholesterol and high LDL
cholesterol were associated with lower risk. Triglycerides, blood pressure, and use of statins
were not associated with risk of VTE. After additional adjustment for BMI, there seemed to
be a trend toward a lower VTE risk with higher LDL level, while no other associations were
observed between physiologic characteristics and risk of VTE. Results were similar in
secondary analyses when we added constants to account for the antihyperlipidaemic and
antihypertensive medications (data not shown). In addition, there were no interactions of age
with all of the CVD risk factors with p-value < 0.05 after accounting for multiple testing.
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Using a time-dependent analysis, we found that current smoking and obesity were the only
atherosclerotic CVD risk factors associated with risk of VTE. Physical activity was
inversely associated with risk of VTE, but was confounded by obesity. Alcohol use,
diabetes, hypertension, or lipid levels were not associated with VTE risk. The same findings
were observed for unprovoked and provoked VTE.
The findings of our study are in contradiction to a published meta-analysis (8). In that study,
obesity, hypertension, diabetes mellitus, triglycerides, and low HDL were risk factors for
VTE in unadjusted analyses, raising the possibility that risk factor modifications may help
reduce VTE risk. However, the meta-analysis was based on pooling both case-control and
cohort studies with different populations and inclusion criteria. Furthermore, a major
limitation of this meta-analysis is that the analyses did not adjust for important confounders
such as age and obesity, which are known to associate with both CVD risk factors and VTE.
Hence, this particular issue makes interpretation of this meta-analysis very difficult as
reported positive findings could be due to confounding.
Whether CVD risk factors increase VTE risk has been a focus of many cohort and case-
control studies. Most studies (6,7,16–19), including ours, agree that current smoking is
associated with increased VTE risk. A Danish study found a dose-response relationship
between smoking and VTE risk. The relative risk for VTE (both unprovoked and provoked
VTE) was 2.6 (95%CI: 1.5 – 4.7) for those currently smoking > 25 cigarettes per day
compared to non-smokers (17). Biologically, smoking’s association with VTE may be
mediated through hypercoagulability and impaired fibrinolysis (20). Hence, smoking
cessation may not only decrease the risk of arterial atherosclerosis, but also VTE. However,
some studies failed to show an association of smoking with VTE (5, 21–23). In a prior LITE
publication (5), which included 19,293 men and women from the ARIC and CHS studies,
Tsai et al. reported that former or current smokers were not at higher risk for VTE compared
to non-smokers. The discrepancy between that analysis and our current analysis may be
explained by the fact that the Tsai analysis had a shorter follow-up time (median 8 years vs.
15.5 years in our study), fewer events, and included participants > 65 years from the CHS
study.
Our findings corroborate well documented findings that obesity is an important VTE risk
factor (5–7,16,18,24,25). Existing literature on the relation between physical activity and
VTE risk has been inconclusive, with some studies reporting that physical activity is
associated with lower VTE risk (26), others showing that physical activity is associated with
higher VTE risk (27, 28), and others reporting no association (5,6). In this analysis, physical
inactivity was associated with a higher risk of incident VTE, but this was attenuated after
accounting for BMI. Obesity likely resides on the causal pathway between physical
inactivity and VTE, therefore the observed attenuation of the association with adjustment for
BMI is not surprising.
The roles of diabetes, hypertension, and dyslipidemia in the pathogenesis of VTE risk are
controversial. The LITE study by Tsai et al. previously reported that diabetes was a modest
risk factor for VTE (5), whereas our findings did not corroborate this. Other studies reported
that diabetes did not increase VTE risk (6,16,29, 30) or that the association was confounded
by other VTE risk factors such as major surgery, medical illness, or residence in a nursing
home (31).
Our analyses also showed no relation between hypertension and risk of incident VTE.
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Consistent with our findings, the Copenhagen Heart Study reported no association between
SBP and VTE (6). Based on a self-reported questionnaire, however, the Nurses’ Health
Study, which followed 112,822 women 30 to 55 years of age over 16 years, reported that
hypertension, after multivariable adjustment (including obesity), was a modest risk factor for
VTE, with HR = 1.5 (95%CI: 1.2–2.0) (16).
Few studies specifically examined the association of lipid levels and VTE. In this analysis,
after accounting for BMI, high LDL level appeared to be associated with lower VTE risk.
The explanation for this finding is unclear and is perhaps related to chance. Levels of HDL
cholesterol and triglycerides, however, were unrelated to VTE risk. Another previous LITE
analysis reported that HDL cholesterol, subfractions of HDL cholesterol (HDL-2 and
HDL3), and apolipoprotein A–I were not associated with VTE (32). The Copenhagen Heart
Study also reported no association of dyslipidaemia with VTE (6). In contrast, a small case-
control study suggested that men < 55 years with VTE had low levels of HDL and elevated
levels of LDL compared to matched controls (33). Lipoprotein subclass analyses showed
that these differences reflected lower levels of large HDL particles and higher levels of
small LDL particles.
Although we unexpectedly observed an inverse association between LDL level and VTE
risk, statin treatment when evaluated independently (Table 2) was in the direction of lower
VTE risk, but was not statistically significant. The JUPITER trial (34) and a post-trial
analysis of the Heart and Estrogen/progestin Replacement Therapy Study (HERS) (35)
showed a reduction in VTE risk with statin therapy. The beneficial effects of statins are
thought to be mediated through reduction of thrombin generation and increased activity of
the protein C anticoagulant pathway (20, 36), not the reduction of cholesterol levels. It is
possible that we failed to observe a significant association between statins and VTE risk due
to lack of statistical power, as there were relatively few events among statin users.
In several instances prior studies reported associations between diabetes, hypertension, and
dyslipidaemia and risk of VTE, while in this re-analysis of the LITE data we did not. It is
possible that the studies reporting positive associations may have overestimated the risk due
to residual confounding, and perhaps by obesity. These studies also usually measured the
risk factors only once at baseline. In our study, we adjusted for changes in clinical
characteristics and use of medications.
Strengths of our study are that this is a large, well-designed epidemiologic study.
Measurements of CVD risk factors and validation of VTE events were standardised. The
large sample size of the study should have provided sufficient power to detect associations
of CVD risk factors on VTE risk. Furthermore, participants were examined and covariates
were adjusted and updated during the follow-up time prior to onset of VTE. We also
acknowledge limitations. Given that many participants had multiple CVD risk factors, it is
conceivable that some may have died from competing risk such as arterial events prior to the
development of VTE. In addition, VTE cases would have been missed if VTE events were
not hospitalised or recognised by clinicians. These limitations are true of many
epidemiologic studies and would typically lead to bias toward finding no association
between risk factors and VTE. Lastly, although the follow-up period ended in 2005, data on
CVD risk factors were available and updated serially between 1987–1998.
Among the well-established risk factors for atherosclerotic CVD, only smoking and obesity
were independently associated with VTE risk in this study. This finding corroborates that
the pathogenesis of venous disease is different from that of atherosclerotic disease.
Avoidance of smoking and obesity may help prevent both venous and arterial diseases.
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What is known about this topic?
• It is unclear whether cardiovascular disease risk factors increase risk of venous
thromboembolism (VTE).
• Prior studies consistently reported that obesity is associated with VTE.
However, the associations between other cardiovascular disease risk factors and
VTE are inconsistent.
• One criticism for inconsistent finding is that these cardiovascular disease risk
factors, which are known to fluctuate over time, are usually measured only once
at baseline when VTE events occurred many years after the initial
measurements. This makes it difficult to demonstrate associations.
What does this paper add?
• This study analyses the associations between cardiovascular disease risk factors
and VTE risk by serially updating risk factors and adjusting for use of anti-
hypertensive and cholesterol lowering medications during follow-up time.
• The results should help clarify the associations.
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Table 1
Participant characteristics by visit, ARIC 1987–1998 (1).
Visit number V1 (1987–1989) V2 (1990–1992) V3 (1993–1995) V4 (1996–1998)
N 15340 13867 12368 11068
Demographics
Age, years (SD) 54.1 (5.8) 57.0 (5.7) 59.9 (5.7) 62.7 (5.7)
African-Americans, n (%) 4114(26.8) 3430(24.7) 2856(23.1) 2503 (22.6)
Male, n (%) 6905 (45.0) 6210 (44.8) 5486 (44.4) 4867 (44.0)
Behaviours
Physical activity, n (%)2
 Q1 4343 (28.4) - 3046 (24.8) -
 Q2 3600 (23.6) - 2685 (21.9) -
 Q3 4297 (28.1) - 3676 (30.0) -
 Q4 3035 (19.9) - 2864 (23.3) -
HRT use among women, n (%)3 1654 (19.9) 2252 (27.0) 2779 (33.4) 2758 (33.4)
Smoking, n (%)
 Never 6379 (41.6) 5487 (39.7) 5065 (41.1) 4564 (41.7)
 Former 4926 (32.1) 5245 (37.9) 5057 (41.0) 4745 (43.3)
 Current 4020 (26.2) 3103 (22.4) 2207 (17.9) 1647 (15.0)
Alcohol intake in g/week, n (%)
 0 9340 (61.3) 9155 (65.9) 7774 (63.6) 7435 (67.9)
 1–99 3737 (24.5) 3027 (21.9) 2896 (23.7) 2277 (20.8)
 ≥100 2159 (14.2) 1686 (12.2) 1561 (12.8) 1237 (11.3)
BMI, kg/m2, n (%)
 <25 5092 (33.3) 4327 (31.3) 3424 (27.7) 2823 (25.6)
 25 – 29 6031 (39.4) 5527 (39.9) 4863 (39.4) 4391 (39.8)
 30 – 34 2819 (18.4) 2651 (19.2) 2634 (21.3) 2471 (22.4)
 ≥35 1373 (9.0) 1334 (9.6) 1429 (11.6) 1346 (12.2)
Physiologic characteristics
Diabetes status, n (%)
 Normal 7742 (50.9) 5112 (37.0) 5692 (48.4) 5115 (46.8)
 IFG 5649 (37.1) 6602 (47.8) 4447 (36.1) 3995 (36.5)
 Prevalent diabetes 1829 (12.0) 2090 (15.1) 1898 (15.4) 1826 (16.7)
BP, mmHg, n (%)
 Systolic
  <120 7873 (51.4) 7111 (51.3) 5394 (43.6) 4006 (36.2)
  120–139 5112 (33.4) 4580 (33.0) 4574 (37.0) 4399 (39.8)
  ≥140 2341 (15.3) 2171 (15.7) 2394 (19.4) 2648 (24.0)
 Diastolic
 <80 11106 (72.5) 10834 (78.2) 9659 (78.1) 8905 (80.6)
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Visit number V1 (1987–1989) V2 (1990–1992) V3 (1993–1995) V4 (1996–1998)
 80–89 3037 (19.8) 2283 (16.5) 2088 (16.9) 1690 (15.3)
 ≥90 1183 (7.7) 746 (5.4) 615 (5.0) 458 (4.1)
HTN, n (%) 5319 (34.9%) 4951 (35.8%) 5009 (40.7%) 5193 (47.1%)
BP med, n(%) 4638 (30.3) 4489 (32.4) 4589 (37.1) 4735 (42.8)
Lipid values, mg/dl, n (%)
HDL cholesterol
 <40 4025 (26.7) 4067 (29.6) 3039 (24.7) 3070 (28.0)
 40–59 7087 (46.9) 6437 (46.8) 5806 (47.2) 5217 (47.6)
 ≥60 3989 (26.4) 3239 (23.6) 3470 (28.2) 2685 (24.5)
LDL cholesterol
 <100 2382 (16.0) 2285 (16.9) 2564 (21.2) 2651 (24.6)
 100 – 129 4225 (28.4) 4306 (31.8) 4077 (33.6) 3933 (36.4)
 130 – 159 4406 (29.6) 4069 (30.0) 3525 (29.1) 2856 (26.5)
 ≥160 3866 (26.0) 2887 (21.3) 1959 (16.2) 1356 (12.6)
Triglycerides
 <150 10904 (72.2) 9653 (70.0) 8161 (66.3) 7189 (65.5)
 150 – 199 2157 (14.3) 2080 (15.1) 2130 (17.3) 1855 (16.9)
 ≥200 2041 (13.5) 2050 (14.9) 2024 (16.4) 1928 (17.6)
Lipid lowering medication, n (%) 431 (2.8) 860 (6.2) 1155 (9.4) 1539 (14.0)
Statin use, n (%) 81 (0.5) 322 (2.3) 668 (5.4) 1215 (11.0)
1
Participants who reported a history of VTE and/or anticoagulant use at baseline were excluded. Participants who reported anticoagulant use at
follow-up were excluded at the visit before use was reported. Values are mean (SD) or n (%).
2
Only measured at visit 1 and visit 3.
3
Only measured at visit 1. ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; HRT, hormone replacement therapy; Q, quartile;
SD, standard deviation; V, visit; HTN, hypertension; BP, blood pressure.
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